NovoMedix is developing novel classes of small molecule therapeutics for hard-to-treat cancers such as triple negative breast tumors and high-risk childhood leukemia.

Our orally bioavailable novel drug candidates modulate multiple biological pathways that are critical drivers of disease, and are relatively inactive in normal tissues and housekeeping processes. Preclinical studies have shown that these drug candidates provide wide therapeutic windows with better efficacy than traditional chemotherapy.

Copyright © 2014 NovoMedix LLC, All rights reserved.